Cargando…

Response to “Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice”

Detalles Bibliográficos
Autores principales:	Blumenfeld, Andrew M., Silberstein, Stephen D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756747/ https://www.ncbi.nlm.nih.gov/pubmed/33107587 http://dx.doi.org/10.1111/head.13996

Ejemplares similares

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
por: Silberstein, Stephen D, et al.
Publicado: (2015)

OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
por: Pedraza, María Isabel, et al.
Publicado: (2015)

The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
por: Silberstein, S, et al.
Publicado: (2013)

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
por: Aurora, SK, et al.
Publicado: (2014)

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
por: Byun, Jung-Ick, et al.
Publicado: (2017)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
por: Aurora, SK, et al.
Publicado: (2013)

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
por: Diener, HC, et al.
Publicado: (2013)

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
por: Blumenfeld, Andrew M, et al.
Publicado: (2019)

OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
por: Dodick, D, et al.
Publicado: (2013)

Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
por: Pijpers, Judith A, et al.
Publicado: (2020)

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
por: Matharu, Manjit, et al.
Publicado: (2017)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Rothrock, John F., et al.
Publicado: (2019)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine
por: Bratbak, Daniel Fossum, et al.
Publicado: (2016)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice
por: Paolucci, Matteo, et al.
Publicado: (2015)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2020)

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
por: Lipton, Richard B, et al.
Publicado: (2016)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
por: Blumenfeld, Andrew M., et al.
Publicado: (2018)

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid
por: Ferrari, Michel D., et al.
Publicado: (2022)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety
por: Szok, Délia, et al.
Publicado: (2015)

OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
por: Chiang, Chia-Chun, et al.
Publicado: (2017)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
por: Sastre Real, María, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_991n6orm28ph5rorehjloalvfh